Overview

Losartan for the Treatment of Pediatric NAFLD

Status:
Terminated

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator:

Johns Hopkins University

Treatments:

Losartan